Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J. Naber
P2.13-03 Real-Life Experience With Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Brigatinib Bei ALK-positivem NSCLC
Im Focus Onkologie
P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
HER2 Regulates Cancer Stem-Like Cell Phenotype in ALK Translocated NSCLC
International Journal of Oncology
Cancer Research
Oncology
P1.15-03 Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC From Real-World Data (RWD)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pcn216 - Contemporary Real-World Evidences on Alk+ NSCLC Patients in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P2.13-01 Brigatinib Use in England – Where Next?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
